We are international
Donate
TEXT SIZE   
    back

2010 ASCO Annual Meeting

The IMF brings you highlights from the annual meeting of the American Society of Clinical Oncology held June 4-8 in Chicago, Illinois.

These videos are now up on the web, along with the presentation abstracts and slides where available. If you have any issues with the videos not playing properly, please upgrade your Adobe Flash Player.This is free software provided by Adobe Systems.

Velcade
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, California, USA
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, USA

ASCO 2010: Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
Frits Van Rhee, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA

ASCO 2010: Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
Philippe Moreau, MD
Hôpital de Nantes
Nantes, France
ASCO 2010: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

ASCO 2010: Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.
Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota, USA
ASCO 2010: Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
Sundar Jagannath, MD
Mt. Sinai Medical Center
New York, New York, U.S.A.

ASCO 2010: Response of newly diagnosed myeloma with 1q21 amplification to bortezomib-based PAD induction therapy.
Douglas Joshua, MD
University of Sydney
Sydney, Australia